5-溴-2-乙氧基苯甲酸甲酯 | 773873-65-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 5-溴-2-乙氧基苯甲酸甲酯
• 英文名称: methyl 5-bromo-2-ethoxybenzoate
• 英文别名: 2-ethoxy-5-bromo-benzoic acid methyl ester；2-Aethoxy-5-brom-benzoesaeure-methylester；Aethylaether-5-brom-salicylsaeure-methylester
• CAS: 773873-65-7
• 化学式: C₁₀H₁₁BrO₃
• 分子量: 259.1
• InChiKey: KBGPOLKFTBVLCH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  35.5
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 海关编码：
  2918990090

反应信息

• 作为反应物：
  描述：

  5-溴-2-乙氧基苯甲酸甲酯 在 一水合肼 作用下， 以 乙醇 为溶剂， 反应 1.0h， 生成 5-Bromo-2-ethoxybenzohydrazide
  参考文献：
  名称：

  Optimization and structure–activity relationships of a series of potent inhibitors of methicillin-resistant Staphylococcus aureus (MRSA) pyruvate kinase as novel antimicrobial agents

  摘要：

  A novel series of hydrazones were synthesized and evaluated as inhibitors of methicillin-resistant Staphylococcus aureus (MRSA) pyruvate kinase (PK). PK has been identified as one of the most highly connected 'hub proteins' in MRSA. PK has been shown to be critical for bacterial survival which makes it a potential target for development of novel antibiotics and the high degree of connectivity implies it should be very sensitive to mutations and thus less able to develop resistance. PK is not unique to bacteria and thus a critical requirement for such a PK inhibitor would be that it does not inhibit the homologous human enzyme(s) at therapeutic concentrations. Several MRSA PK inhibitors (including 8d) were identified using in silico screening combined with enzyme assays and were found to be selective for bacterial enzyme compared to four human PK isoforms (M1, M2, R and L). However these lead compounds did not show significant inhibitory activity for MRSA growth presumably due to poor bacterial cell penetration. Structure-activity relationship (SAR) studies were carried out on 8d and led us to discover more potent compounds with enzyme inhibiting activities in the low nanomolar range and some were found to effectively inhibit bacteria growth in culture with minimum inhibitory concentrations (MIC) as low as 1 mu g/mL. These inhibitors bind in two elongated flat clefts found at the minor interfaces in the homo-tetrameric enzyme complex and the observed SAR is in keeping with the size and electronic constraints of these binding sites. Access to the corresponding sites in the human enzyme is blocked. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2012.10.002
• 作为产物：
  描述：

  甲醇 、 5-氯-2-乙氧基苯甲酸 在 盐酸 作用下， 生成 5-溴-2-乙氧基苯甲酸甲酯
  参考文献：
  名称：

  Changes in Bone Structure and Mass With Advancing Age in the Male C57BL/6J Mouse

  摘要：

  为了确定小鼠是否在衰老过程中失去骨骼，以及这些变化是否模仿人类衰老过程中观察到的变化，我们使用微计算机断层扫描（μCT）研究了雄性C57BL/6J小鼠在其生命周期内胫骨干骺和干骼的变化。在6周到24个月之间，骨松质体积比（BV/TV）下降了60%。骨量损失的特征表现为小梁数目降低（Tb.N）、小梁间距增加（Tb.Sp）以及连通性下降。随着年龄的增长，各向异性降低，而结构模型指数上升。皮质骨厚度在6周到6个月之间增加，然后持续下降至24个月（下降12%）。皮质骨面积（Ct.Ar）在6到24个月期间保持不变。去脂重在12个月达到顶峰，然后逐渐下降至24个月。12到24个月之间的总体质量损失达到了10%。总体而言，小鼠在骨骼质量和结构方面的年龄相关变化与人类的衰老过程非常相似。此外，骨松质的早期快速损失表明，骨骼丧失并不仅仅与小鼠的老年相关，而是在早期生长阶段就开始发生的连续性过程。我们得出结论，C57BL/6J雄性小鼠可能是研究人类年龄相关骨质流失某些方面的一个有用模型。

  DOI：

  10.1359/jbmr.2002.17.6.1044

文献信息

• [EN] ANTI-BACTERIAL PYRUVATE KINASE MODULATOR COMPOUNDS, COMPOSITIONS, USES, AND METHODS<br/>[FR] COMPOSÉS ANTIBACTÉRIENS MODULATEURS DE LA PYRUVATE KINASE, COMPOSITIONS, UTILISATIONS ET MÉTHODES ASSOCIÉES
  申请人：UNIV BRITISH COLUMBIA

  公开号：WO2012051708A1

  公开（公告）日：2012-04-26

  Compounds having a structure of Formulas A-C are provided. Uses of such compounds as an antibiotic, including both gram-negative and gram-positive micro-organisms, as well as methods of treatment and uses involving such compounds are provided.

  提供了具有A-C式结构的化合物。提供了这些化合物作为抗生素的用途，包括革兰氏阴性和革兰氏阳性微生物，以及涉及这些化合物的治疗方法和用途。
• [EN] TRIAZOLONE COMPOUNDS AND USES THEREOF<br/>[FR] COMPOSÉS DE TRIAZOLONE ET LEURS UTILISATIONS
  申请人：INCEPTION 2 INC

  公开号：WO2015035059A1

  公开（公告）日：2015-03-12

  The invention disclosed herein is directed to compounds of Formula (la) and (lb) and pharmaceutically acceptable salts thereof, which are useful in the treatment of prostate, breast, colon, pancreatic, human chronic lymphocyticδ leukemia, melanoma and other cancers. The invention also comprises pharmaceutical compositions comprising a therapeutically effective amount of compound of Formula (la) or (lb), or a pharmaceutically acceptable salt thereof. The invention disclosed herein is also directed to methods of treating prostate, breast, ovarian, liver, kidney, colon, pancreatic, human chronic lymphocytic leukemia, melanoma and other cancers. The invention disclosed herein is further directed to methods of treating prostate, breast, colon, pancreatic, chronic lymphocytic leukemia, melanoma and other cancers comprising administration of a therapeutically effective amount of a compound which is a dual antagonist of PPARα and PPARδ. The compounds and pharmaceutical compositions of the invention are also useful in the treatment of viral infections, such as HCV infections and HIV infections. The invention disclosed herein is also directed to a methods of preventing the onset of and/or recurrence of acute and chronic myeloid leukemia, as well as other cancers, comprising administration of a herapeutically effective amount of a dual antagonist of PPARα and PPARδ.

  本发明涉及式（Ia）和（Ib）化合物及其药学上可接受的盐，用于治疗前列腺、乳腺、结肠、胰腺、人类慢性淋巴细胞白血病、黑色素瘤和其他癌症。该发明还包括含有式（Ia）或（Ib）化合物或其药学上可接受的盐的治疗有效量的药物组合物。本发明还涉及治疗前列腺、乳腺、卵巢、肝脏、肾脏、结肠、胰腺、人类慢性淋巴细胞白血病、黑色素瘤和其他癌症的方法。本发明还涉及治疗前列腺、乳腺、结肠、胰腺、慢性淋巴细胞白血病、黑色素瘤和其他癌症的方法，包括给予对PPARα和PPARδ具有双重拮抗作用的化合物的治疗有效量。本发明的化合物和药物组合物还可用于治疗病毒感染，如HCV感染和HIV感染。本发明还涉及一种预防急性和慢性骨髓性白血病以及其他癌症发作和/或复发的方法，包括给予对PPARα和PPARδ具有双重拮抗作用的化合物的治疗有效量。
• TRIAZOLONE COMPOUNDS AND USES THEREOF
  申请人：INCEPTION 2, INC.

  公开号：US20160194292A1

  公开（公告）日：2016-07-07

  The invention disclosed herein is directed to compounds of Formula (1a) and (1b) and pharmaceutically acceptable salts thereof, which are useful in the treatment of prostate, breast, colon, pancreatic, human chronic lymphocyticδ leukemia, melanoma and other cancers. The invention also comprises pharmaceutical compositions comprising a therapeutically effective amount of compound of Formula (1a) or (1b), or a pharmaceutically acceptable salt thereof. The invention disclosed herein is also directed to methods of treating prostate, breast, ovarian, liver, kidney, colon, pancreatic, human chronic lymphocytic leukemia, melanoma and other cancers. The invention disclosed herein is further directed to methods of treating prostate, breast, colon, pancreatic, chronic lymphocytic leukemia, melanoma and other cancers comprising administration of a therapeutically effective amount of a compound which is a dual antagonist of PPARα and PPARδ. The compounds and pharmaceutical compositions of the invention are also useful in the treatment of viral infections, such as HCV infections and HIV infections. The invention disclosed herein is also directed to a methods of preventing the onset of and/or recurrence of acute and chronic myeloid leukemia, as well as other cancers, comprising administration of a herapeutically effective amount of a dual antagonist of PPARα and PPARδ.

  本发明涉及式（1a）和（1b）的化合物及其药学上可接受的盐，用于治疗前列腺、乳腺、结肠、胰腺、人类慢性淋巴细胞白血病、黑色素瘤和其他癌症。本发明还包括含有化合物式（1a）或（1b）或其药学上可接受的盐的治疗有效量的制剂。本发明还涉及治疗前列腺、乳腺、卵巢、肝脏、肾脏、结肠、胰腺、人类慢性淋巴细胞白血病、黑色素瘤和其他癌症的方法。本发明还涉及通过给予既是PPARα又是PPARδ双重拮抗剂的化合物的治疗有效量来治疗前列腺、乳腺、结肠、胰腺、慢性淋巴细胞白血病、黑色素瘤和其他癌症的方法。本发明的化合物和制剂也可用于治疗病毒感染，如HCV感染和HIV感染。本发明还涉及通过给予PPARα和PPARδ双重拮抗剂的治疗有效量来预防急性和慢性髓细胞白血病以及其他癌症的发生和/或复发的方法。
• Kinetics and mechanism of aromatic halogenation by hypohalous acids. Part II. Directive effects of substituents in the bromination of aromatic ethers by hypobromous acid
  作者：S. J. Branch、Brynmor Jones

  DOI：10.1039/jr9550002921

  日期：——
• Sluka, Jaroslav; Smejkal, Frantisek; Budesinsky, Zdenek, Collection of Czechoslovak Chemical Communications, 1980, vol. 45, # 5, p. 1595 - 1600
  作者：Sluka, Jaroslav、Smejkal, Frantisek、Budesinsky, Zdenek

  DOI：——

  日期：——